NASDAQ:ATOS Atossa Genetics Q3 2025 Earnings Report $1.90 -0.15 (-7.32%) Closing price 09/25/2026 04:00 PM EasternExtended Trading$1.92 +0.02 (+1.05%) As of 09/25/2026 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Atossa Genetics EPS ResultsActual EPS-$1.05Consensus EPS -$1.05Beat/MissMet ExpectationsOne Year Ago EPSN/AAtossa Genetics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAtossa Genetics Announcement DetailsQuarterQ3 2025Date11/12/2025TimeBefore Market OpensConference Call DateWednesday, November 12, 2025Conference Call Time8:30AM ETUpcoming EarningsAtossa Genetics' Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Atossa Genetics Earnings HeadlinesAtossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of AgingSeptember 24 at 8:00 AM | prnewswire.comAtossa Genetics Inc. (NASDAQ:ATOS) Given Consensus Recommendation of "Hold" by BrokeragesSeptember 20, 2026 | americanbankingnews.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.September 26 at 1:00 AM | Porter & Company (Ad)Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate UpdateAugust 7, 2026 | prnewswire.comATOSSA THERAPEUTICS INCJuly 31, 2026 | finanznachrichten.deAtossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast CancerJuly 28, 2026 | prnewswire.comSee More Atossa Genetics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Atossa Genetics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Atossa Genetics and other key companies, straight to your email. Email Address About Atossa GeneticsAtossa Genetics (NASDAQ:ATOS), Inc., now operating as Atossa Therapeutics, Inc. (NASDAQ: ATOS), is a clinical-stage biopharmaceutical company focused on developing therapies for breast cancer and other diseases affecting breast tissue. The company’s research is centered on targeted treatments intended to address unmet needs in the prevention and treatment of breast cancer. Atossa’s principal investigational product is oral endoxifen, a selective estrogen receptor modulator being evaluated in clinical studies involving patients with hormone receptor-positive breast cancer. The company has studied endoxifen in several settings, including the presurgical treatment of breast cancer and approaches intended to reduce the risk of developing or recurring breast cancer. Its development programs remain subject to clinical testing and regulatory review. Founded in 2009, the company was originally known as Atossa Genetics before adopting the Atossa Therapeutics name to reflect its broader therapeutic development focus. Atossa is headquartered in Seattle, Washington, and its clinical research activities may involve sites and collaborators in multiple regions. Steven Quay, M.D., Ph.D., is the company’s founder and chief executive officer.View Atossa Genetics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/21 - 09/25Costco Ends Its Fiscal Year on a High Note, Eyes Big ExpansionCracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic ProblemDarden Restaurants Serves Up Fresh Catalysts for a Stock Price RallySoFi Is Bypassing the Banking Bottleneck With Stablecoin SettlementSuper Micro’s Vera Rubin Shipments Put Its AI Infrastructure Advantage to the TestHims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
